CD4 News and Research

RSS

ART associated with reduced risk of HIV transmission to sexual partners, study shows

Research published in the Lancet online Thursday "provides the strongest evidence to date" that antiretroviral therapy might also be used to prevent transmission of HIV, Agence France-Presse reports. The observational study found that treating HIV-positive patients with ART reduced the risk of HIV transmission to their sexual partners by 92 percent (5/26).

28 May 2010

Media outlets highlight studies presented at International Microbicides Conference

A study in Africa, presented Sunday at the International Microbicides Conference (M2010) in Pittsburgh, has shown that a man's risk of HIV infection doubles if his HIV-positive partner is pregnant, according to HealthDay News/U.S. News & World Report.

25 May 2010

New study indicates pregnancy can double HIV risk in men

Young women of reproductive-age are among those at greatest risk of acquiring HIV, and several studies have suggested that during pregnancy women are even more susceptible to infection.

24 May 2010

Study: Th1 cells play a vital role in pathogenesis of immune-mediated diseases

Current research suggests that T helper-type 1 (Th1) cells, previously thought to mediate autoimmunity, may actual inhibit the development of experimental immune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), by suppressing Th17 cells.

24 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

HIV disease tends to progress at faster rate in infected individuals who consume more alcoholic drinks

HIV disease tends to progress at a faster rate in infected individuals who consume two or more alcoholic drinks a day, according to an important new paper in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc.

14 May 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).

12 May 2010

New CD4 test kit can improve quality of life for HIV and AIDS patients

The use of rapid point-of-care diagnostic tests for the measurement of CD4 T-cells, a marker of the immune system will be an important factor in improving the lives of people living with HIV and AIDS especially in developing and resource-poor countries.

7 May 2010

Liver transplant recipients develop premature immune senescence: Researchers

Researchers at the University of Cambridge found that liver transplant recipients develop premature immune senescence, the normal process by which the immune system ages and becomes less effective. Full details appear in the May issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

30 Apr 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute to conduct an investigator sponsored Phase II clinical trial.

30 Apr 2010

CD8+T cells may aid in developing AIDS vaccine: New Journal of Physics

Limited success in modelling the behaviour of the complex, unusual and unpredictable HIV virus has slowed efforts to develop an effective vaccine to prevent AIDS.

29 Apr 2010

Study examines lifestyle-related causes of death in AIDS patients

The study, by researchers from the University of Bristol and a large group of international collaborators, examined data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) which involved nearly 40,000 patients who started ART between 1996 and 2006 in Europe and North America.

29 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Causes of death in AIDS patients

New research shows that Antiretroviral Therapy (ART) continues to dramatically reduce rates of mortality from HIV infection in high-income countries, such that non-AIDS-related deaths exceed AIDS deaths after approximately four years of taking ART.

28 Apr 2010

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.

27 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

New data on Cladribine Tablets presented at AAN annual meeting

EMD Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that new data providing further understanding on Cladribine Tablets as a potential new therapeutic option for relapsing forms of multiple sclerosis were presented at the 62nd Annual Meeting of the American Academy of Neurology.

17 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010